Lv11
70 积分 2023-11-23 加入
MO15.01: CXCL9+ DCs and CXCR3+ Tregs Drive Neoadjuvant Chemoimmunotherapy Resistance in Limited-Stage SCLC
1小时前
求助中
High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial
7个月前
已完结
Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer
8个月前
已完结
Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
9个月前
已完结
Survival and prognostic factors of HER2-mutant advanced non-small cell lung cancer with brain metastases
9个月前
已完结
Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers
9个月前
已完结
[Treatment of oligoprogression to immunotherapy resistance in advanced non-small cell lung cancer]
9个月前
已完结
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study
9个月前
已完结
SBRT for oligoprogressive disease: using the evidence to maximise the benefits
9个月前
已完结
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
9个月前
已完结